Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immune cells in cancer, Cancer Cells and Metastasis, and Immunotherapy and Immune Responses.
Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.
Supplementary Tables 1 from Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Supplementary Figures 1 from Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Data from Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Supplementary Tables 1 from Poor outcome in postpartum breast cancer patients is associated with distinct molecular and immunological features
Supplementary Figures 1 from Poor outcome in postpartum breast cancer patients is associated with distinct molecular and immunological features
Supplementary Figures 1 from Poor outcome in postpartum breast cancer patients is associated with distinct molecular and immunological features
Supplementary Tables 1 from Poor outcome in postpartum breast cancer patients is associated with distinct molecular and immunological features
Data from Poor outcome in postpartum breast cancer patients is associated with distinct molecular and immunological features
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
Mechanisms driving the immunoregulatory function of cancer cells.
IL-5-producing CD4<sup>+</sup> T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.
Immunoediting instructs tumor metabolic reprogramming to support immune evasion.
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
Neoadjuvant immune checkpoint blockade triggers persistent and systemic T<sub>reg</sub> activation which blunts therapeutic efficacy against metastatic spread of breast tumors.
p53 deficient breast cancer cells reprogram preadipocytes toward tumor-protective immunomodulatory cells
Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features.
Supplementary Data from CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis
Data from CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis
Supplementary Data from CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis
Supplementary Data from CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis
Data from CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis
Supplementary Data from CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis
Supplementary Data from CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis
Supplementary Tables 1 from Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Supplementary Figures 1 from Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Supplementary Data from CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis
Supplementary Tables 1 from Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features